Eli Lilly and Company (NYSE:LLY) Shares Bought by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH increased its holdings in Eli Lilly and Company (NYSE:LLY) by 13.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,533 shares of the company’s stock after purchasing an additional 307 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Eli Lilly and Company were worth $2,092,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Mogy Joel R Investment Counsel Inc. raised its holdings in Eli Lilly and Company by 11.4% in the 1st quarter. Mogy Joel R Investment Counsel Inc. now owns 39,001 shares of the company’s stock worth $32,211,000 after purchasing an additional 3,993 shares during the period. Allen Mooney & Barnes Investment Advisors LLC raised its holdings in Eli Lilly and Company by 1.7% in the 1st quarter. Allen Mooney & Barnes Investment Advisors LLC now owns 5,336 shares of the company’s stock worth $4,407,000 after purchasing an additional 88 shares during the period. Sterling Financial Group Inc. raised its holdings in Eli Lilly and Company by 8.7% in the 1st quarter. Sterling Financial Group Inc. now owns 412 shares of the company’s stock worth $340,000 after purchasing an additional 33 shares during the period. Ferguson Wellman Capital Management Inc. increased its stake in Eli Lilly and Company by 1.3% during the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 21,098 shares of the company’s stock worth $17,425,000 after buying an additional 278 shares in the last quarter. Finally, Defined Financial Planning LLC increased its stake in Eli Lilly and Company by 6.6% during the 1st quarter. Defined Financial Planning LLC now owns 421 shares of the company’s stock worth $339,000 after buying an additional 26 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of several research reports. Erste Group Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price objective for the company. Hsbc Global Res lowered Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. Finally, Wall Street Zen upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Saturday, June 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,011.37.

Eli Lilly and Company Trading Up 0.8%

Shares of Eli Lilly and Company stock opened at $818.56 on Friday. The firm has a market capitalization of $775.78 billion, a price-to-earnings ratio of 69.90, a PEG ratio of 1.40 and a beta of 0.41. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a 50 day moving average of $775.43 and a 200 day moving average of $801.50.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company’s revenue was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.58 earnings per share. As a group, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were given a $1.50 dividend. The ex-dividend date was Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.73%. Eli Lilly and Company’s payout ratio is 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.